talazoparib
FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug
The test is approved to gauge germline BRCA mutations in advanced breast cancer patients who may benefit from treatment with Pfizer's PARP inhibitor Talzenna.
Myriad Genetics Submits Supplementary PMA for BRACAnalysis CDx
The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.